临床肿瘤学杂志

• 论著 • 上一篇    下一篇

EphA1蛋白在卵巢浆液性腺癌中的表达及其临床意义

王海燕,彭李博,王建军,文娟娟,石群立,王璇,王建东
  

  1. 南京军区南京总医院病理科
  • 收稿日期:2014-05-28 修回日期:2014-07-24 出版日期:2014-11-30 发布日期:2014-11-30
  • 通讯作者: 王建东

Expression of EphA1 protein in ovarian serous adenocarcinoma and its clinical significance

WANG Haiyan,PENG Libo,WANG Jianjun,WEN Juanjuan,SHI Qunli,WANG Xuan, WANG Jiandong.   

  1. Department of Pathology, Nanjing General Hospital of Nanjing Military Command
  • Received:2014-05-28 Revised:2014-07-24 Online:2014-11-30 Published:2014-11-30
  • Contact: WANG Jiandong

摘要: 目的 探讨受体酪氨酸激酶EphA1在卵巢浆液性腺癌中的表达水平并分析其与临床病理特征的关系,为筛选可用于卵巢浆液性腺癌的诊断和预后指标提供依据。
方法 采用免疫细胞化学法检测不同人浆液性卵巢癌细胞系HO8910、SKOV3和A2780细胞中EphA1的表达情况。采用免疫组化染色检测EphA1在76例卵巢浆液性腺癌组织中的表达情况,将结果分为:低表达(≤5分)和高表达(>5分);分析EphA1表达与临床病理特征的关系。结果 EphA1在HO8910、SKOV3细胞中呈阴性表达,而在A2780细胞中呈弱阳性表达。76例卵巢浆液性腺癌组织中,EphA1高表达33例(43.4%),低表达43例(56.6%)。EphA1表达与WHO分级、MDACC分级有关(P<0.05),而与临床分期、转移情况、发生部位、肿瘤直径及年龄均无关(P>0.05)。EphA1高表达者的中位总生存期为71.0个月,高于EphA1低表达者的31.0个月,差异有统计学意义(P<0.05)。
结论 EphA1蛋白在卵巢浆液性腺癌中低表达,其表达与组织学分级和预后均有关,有可能成为卵巢浆液性腺癌辅助诊断及临床预后的新指标。

Abstract: Objective To explore the expression level of EphA1 in ovarian serous adenocarcinoma and analyze its correlation with clinicopathological characteristics, as to provide reference for screening a new indicator in ovarian serous adenocarcinoma for diagnosis and prognosis.
Methods The immunocytochemical method was employed to measure the expression of EphA1 in human ovarian cancer cell lines HO8910, SKOV3 and A2780 cells. The protein expression level of EphA1 in 76 ovarian serous adenocarcinoma tissues was detected by immunohistochemical staining. The results were divided into low-level expression(≤5) group and highlevel expression group(>5) according to the immunohistochemical staining counting method. The relationships between the expression of EphA1 and clinicopathological characteristics were investigated. Results The expression of EphA1 protein was negative in HO8910 and SKOV3 cells but weakly positive in A2780 cell. Out of 76 tissue samples of ovarian serous adenocarcinoma, there were 33 cases(43.4%) with high-level expression and 43 cases(56.6%) with low-level expression, respectively. The expression of EphA1 protein was related with WHO and MDACC grading(P<0.05), but unrelated with clinical staging, metastasis, tumor location, tumor diameter and age(P>0.05). The median overall survival of highlevel expression group was 71.0 months, higher than 31.0 months of lowlevel expression group with significant difference(P<0.05).Conclusion Expression of EphA1 protein in ovarian serous adenocarcinoma is downregulated, and is related with high histological grade and poor prognosis. EphA1 protein may be a new index of diagnosis and clinical prognosis in ovarian serous adenocarcinoma.

No related articles found!
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!